Teva to Launch New Growth Strategy at Investor Day
27 April 2023 - 2:35PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
announced today that it will host an Investor Day on Thursday, May
18, 2023 to launch its new growth strategy and portfolio
priorities. The event will take place at the New York Stock
Exchange in New York City. Presentations will begin at 12:00 p.m.
Eastern Time and are expected to conclude at 2:00 p.m. Eastern
Time.
Richard Francis, Teva's President and CEO, will detail a
strategic framework and key priorities focusing on growth and
innovation. Additional members of the executive management team
will share insights into key assets that will drive the company’s
growth engine, review the Company’s innovative R&D pipeline and
discuss efforts to focus the business, as well as outline Teva’s
growth and profitability goals.
Due to limited capacity, in-person attendance is by invitation
only. Analysts and institutional investors will be invited to
pre-register and attend through an invite that will be distributed
separately. For questions regarding the event, please contact
Teva's Investor Relations team at TevaIR@Tevapharm.com.
A live webcast of the event and presentation materials will be
available on Teva's Investor Relations website at:
https://ir.tevapharm.com/Events-and-Presentations.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
innovative medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of innovative and
biopharmaceutical products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the Investor Day conference and webcast, may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, which are based
on management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace; our substantial
indebtedness; our business and operations in general including: the
impact of global economic conditions and other macroeconomic
developments and the governmental and societal responses thereto;
compliance, regulatory and litigation matters; other financial and
economic risks; and other factors discussed in our Annual Report on
Form 10-K for the year ended December 31, 2022, including in the
sections captioned “Risk Factors.” Forward-looking statements speak
only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230427005559/en/
IR: Ran Meir, +1 (267) 468-4475 Yael Ashman, +972 (3) 914
8262 Sanjeev Sharma, +1 (973) 658 2700 PR: Kelley Dougherty,
+1 (973) 832-2810 Eden Klein, +972 (3) 906 2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024